Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Thea Pharma’s New Website for Iyuzeh Support
Thea Pharmaceuticals launched a new website aimed at providing comprehensive resources to ophthalmologists for the effective use of latanoprost ophthalmic solution 0.005%, marketed as Iyuzeh, in patient care. This initiative comes in response to feedback from Eye Care Professionals (ECPs)…
Novel AI Boosts Geographic Atrophy Clinical Trial Efficiency
A new artificial intelligence (AI) system developed by researchers from UCL and Moorfields Eye Hospital could potentially revolutionize the recruitment process for clinical trials aimed at treating Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that…
VSY Biotechnology: Who Will Shine at the OSA 2024?
VSY Biotechnology GmbH, a leading company with innovative ophthalmic solutions, is now accepting submissions for Ophthalmology Star Awards (OSA) 2024 from eye care professionals worldwide. The awards aim to celebrate and promote novel research and advancements in ophthalmology, with winners…
NVISION Eye Centers Partners with Parkhurst NuVision
NVISION Eye Centers, a prominent provider of eye care services nationwide, announced a strategic collaboration with Parkhurst NuVision of San Antonio, Texas, through its subsidiary NVision Clinical Research, LLC. This partnership aims to advance clinical trials in ophthalmology drug development,…
4DMT Receives FDA Clearance of IND for GA Treatment
4D Molecular Therapeutics (4DMT) announced the FDA clearance of its investigational new drug application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine intended for treating geographic atrophy (GA) in patients. Phase 1 GAZE Clinical Trial Details The phase 1…
Novartis’ AMD Drug Linked to Rare Retinal Side Effects
Two recent studies have found that a drug called brolucizumab, which was approved in 2019 and developed by Swiss pharmaceutical company Novartis AG to treat wet age-related macular degeneration (AMD), can cause rare retinal side effects due to its interaction…
Use of Telemedicine in Ophthalmology
The medical industry is undergoing radical change as we enter the digital age. One such change is the advent of telemedicine – a powerful tool enabling healthcare providers to connect with patients remotely. Ophthalmology, the branch of medicine dedicated to…
DORC Receives FDA Clearance for Eva Nexus System
DORC International has announced 510(k) market clearance and the launch of the Eva Nexus. According to DORC, the Eva Nexus features multiple innovations to improve performance, efficiency, and stability for retina surgeons, including Smart IOP for anterior and posterior chamber stability; DORC’s trocar cannula system with HI-FLOW infusion…
Primary Open Angle Glaucoma (POAG)
A subtype of glaucomas known as primary open angle glaucoma (POAG) is characterized by an open, seemingly normal anterior chamber angle and elevated intraocular pressure (IOP), with no additional underlying disease. Secondary glaucoma is a condition where the elevated IOP…
Harrow Starts Triesence Relaunch Strategy
Harrow Pharmaceuticals announced its efforts to relaunch Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL in the United States market. The company announced the successful manufacture of the first of three commercial-scale Process Performance Qualification (PPQ) batches required for the relaunch.…